Skip to main content

Table 2 Patient characteristics according to the rs1214194 genotype

From: Role of genetic variations of chitinase 3-like 1 in bronchial asthmatic patients

rs1214194 genotype

GG (n = 170)

GA (n = 157)

AA (n = 41)

P value

Age, years

57.8 ± 1.2

57.7 ± 1.3

58.4 ± 2.7

NS

Height, cm

158.8 ± 0.7

159.0 ± 0.7

157.7 ± 1.5

NS

Body weight, kg

60.5 ± 1.9

59.6 ± 1.0

59.1 ± 1.9

NS

Sex, n (%)

71 men (42)

71 men (45)

15 men (37)

NS

Age of onset, years

43.5 ± 1.6

43.2 ± 1.7

34.2 ± 3.3

0.032

Eosinophil count/μL

315.6 ± 21.7

310.6 ± 23.4

331.7 ± 46.1

NS

IgE level, IU/mL

473.7 ± 97.5

504.4 ± 101.2

235.7 ± 199.2

NS

GINA asthma severity, n (%)

 Mild

35 (20.6)

34 (21.7)

4 (9.8)

–

 Moderate

70 (41.2)

61 (38.9)

18 (43.9)

–

 Severe

65 (38.2)

62 (39.5)

19 (46.3)

–

Pulmonary function

 %FVC

104.0 ± 2.6

104.0 ± 2.4

97.2 ± 5.9

NS

 FEV1, L

2.3 ± 0.1

2.3 ± 0.1

2.1 ± 0.2

NS

 FEV1/FVC, %

72.4 ± 0.9

72.2 ± 1.0

70.9 ± 1.8

NS

 %FEV1

99.6 ± 2.0

98.8 ± 1.8

87.9 ± 3.6

0.04

  Mild

106.7 ± 4.3

102.7 ± 3.8

91.0 ± 11.8

–

  Moderate

103.1 ± 3.0

99.3 ± 2.8

89.5 ± 5.6

–

  Severe

92.0 ± 3.1

95.1 ± 3.8

85.8 ± 5.4

–

 Equivalent FP CFC dose (μg/day)

325.6 ± 20.8

363.1 ± 22.3

432.1 ± 44.1

NS

  1. Data are expressed as the mean ± standard error
  2. GINA, Global Initiative for Asthma; FVC, forced vital capacity; FEV1, forced expiratory flow volume in one second; NS, not significant among the three groups; FP, fluticasone propionate; CFC, chlorofluorocarbon propellant